2022-06-12: News Headlines

Rainer Shea (2022-06-12). CIA-Backed Terrorism, 'Humanitarian' NGOs, and the Cycle of War Propaganda. orinocotribune.com By Rainer Shea — Jun 9, 2022 | Within Washington's current disinformation campaign targeting Russia, there are a series of traits which reflect a pattern. A pattern that becomes visible when one has studied the cycle of imperialist propaganda long enough. In the 21st century, where sanctions, online narratives, and a dynamic of reignited great-power competition define how imperialism operates, this cycle revolves around exercises in marketing which use "humanitarianism" as the selling point. A network of "human rights" organizations engage in theatrics, manufacturing dramatic stories of atrocities by the ta…

Anders Husby, Lars Kà∏ber (2022-06-11). [Comment] COVID-19 mRNA vaccination and myocarditis or pericarditis. thelancet.com In April, 2021, international news media first reported rare cases of young men in Israel who had developed myocarditis shortly after vaccination with the Pfizer-BioNTech mRNA vaccine against SARS-CoV-2.1 Since then, many observational studies from Asia,2 Europe,3—5 the Middle East,6,7 and North America8,9 have found COVID-19 mRNA vaccination to be associated with a short-term increased risk of myocarditis. Furthermore, this association has been established using multiple types of analysis, including comparisons of observed-to-expected rates,6,8,9 case-control studies,2 self-controlled cases series,3,4 and…

Grace Li, Federica Cappuccini, Natalie G Marchevsky, Parvinder K Aley, Robert Aley, Rachel Anslow, Sagida Bibi, Katrina Cathie, Elizabeth Clutterbuck, Saul N Faust, Shuo Feng, Paul T Heath, Simon Kerridge, Alice Lelliott, Yama Mujadidi, Khuen Foong Ng, Sarah Rhead, Hannah Roberts, Hannah Robinson, Marion R Roderick, Nisha Singh, David Smith, Matthew D Snape, Rinn Song, Karly Tang, Andy Yao, Xinxue Liu, Teresa Lambe, Andrew J Pollard, the COV006 study team (2022-06-11). [Articles] Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6—17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. thelancet.com ChAdOx1 nCoV-19 is well tolerated and immunogenic in children aged 6—17 years, inducing concentrations of antibody that are similar to those associated with high efficacy in phase 3 studies in adults. No safety concerns were raised in this trial.

2022-06-12 23:02 | 17:02 EST | jz | 5 | 0 | 2 | 1 | 0